ScienceDaily (June 21, 2001) — A new test developed with funding from the National Institute of Allergy and Infectious Diseases (NIAID) has been shown to be highly accurate and sensitive for detecting antibodies to Lyme disease. Produced by Immunetics, Inc. of Cambridge, Massachusetts, the new assay recently won approval from the Food and Drug Administration (FDA) for use as a diagnostic test for Lyme disease.

It is the first diagnostic tool to use a synthetic product called C6, a hybrid chemical marker based on components derived from the surface of Borrelia burgdorferi, the tick-borne bacterium that causes Lyme disease. The C6 test is sensitive only to antibodies generated during an active infection.

Lyme disease can be difficult to diagnose, especially in later stages of infection when an individual’s antibodies can fall to very low levels. Laboratory testing showed the C6 approach resulted in a high rate of sensitivity to antibodies from both the early and late stages of Lyme disease. The kit also resulted in fewer false positive readings when compared with current screening methods. Significantly, no false positive readings were obtained when the kit was used to test people who had previously received Lymerix®, the Lyme disease vaccine. Another advantage is the test’s ability to detect antibodies specific to both U.S. and European strains of Borrelia.

“The C6 test is the result of years of collaboration in an ongoing effort to improve our ability to diagnose Lyme disease,” explains microbiologist Phillip Baker, Ph.D., NIAID’s Lyme disease program officer. “This new approach is an important first step in that direction.”

NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institute of Allergy and Infectious Diseases is a component of the National Institutes of Health, U.S. Department of Health and Human Services

Related Stories

More Accurate Test For Lyme Disease Announced By Researcher At The Children's Hospital Of Philadelphia (Mar. 5, 2001) — A new blood test for Lyme disease may provide a more accurate method for detecting the tick-borne illness, particularly in its early stages when current tests may not yield an accurate diagnosis. A ...  > read more

Yale And State Researchers Develop Improved Test For New Tick Disease (Oct. 26, 1999) — Yale and state scientists have developed a new, simpler and more reliable blood test to detect a recently discovered disease called ehrlichiosis, which is carried by deer ticks. The test will make it ...  > read more

Lyme Disease Can Be Prevented With New Shot, Study Suggests (Mar. 20, 2008) — Lyme disease is the blight of countryside users but it may be prevented with a single injection, according to research in the Journal of Medical Microbiology. Researchers found that a new formulation ...  > read more

New Guideline For Treating Lyme Disease (May 25, 2007) — A guideline developed by the American Academy of Neurology finds conventionally recommended courses of antibiotics are highly effective for treating nervous system Lyme disease. However, there is no ...  > read more

Search ScienceDaily

Faster Flu Vaccine